2101 ORAL Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting

J.Jassem; E.Thomas; H.Gomez; R.K.Li; H.C.Chung; L.E.Fein; V.F.Chan; R.A.Peck; P.Mukhopadhyay; H.Roché

首页> 外文期刊>European Journal of Cancer Supplements >2101 ORAL Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting

【24h】

2101 ORAL Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting

机译：蒽环类药物和紫杉烷类药物治疗后转移性乳腺癌（MBC）患者中2101口服依沙贝比隆联合卡培他滨的ORAL III期研究：在一线接受ixabepilone的患者的亚组分析

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共2页
作者
J.Jassem; E.Thomas; H.Gomez; R.K.Li; H.C.Chung; L.E.Fein; V.F.Chan; R.A.Peck; P.Mukhopadhyay; H.Roché;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. [J] . Roche H, Conte P, Perez EA, Breast cancer research and treatment. . 2011,第3期

机译：伊沙贝比隆加卡培他滨治疗转移状态降低的乳腺癌患者，以前接受蒽环类和紫杉烷类药物治疗：通过两项3期临床研究的有效性和安全性数据进行合并分析。
2. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies [J] . Henri Roché, Pierfranco Conte, Edith A. Perez, Breast Cancer Research and Treatment . 2011,第3期

机译：伊沙贝比隆联合卡培他滨治疗转移性乳腺癌患者，以前使用蒽环类药物和紫杉烷类药物治疗后，其表现状态有所下降：根据两项3期临床研究的有效性和安全性数据进行的表现分析
3. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. [J] . Hortobagyi GN, Gomez HL, Li RK, Breast cancer research and treatment. . 2010,第2期

机译：ixabepilone联合卡培他滨与卡培他滨对MBC患者对蒽环类和紫杉烷类耐药的III期研究的总生存期分析。
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. Utilities of metastatic breast cancer patients treated with taxanes compared to utilities of oncology nurses. [D] . Hauser, Robert Sean. 2001

机译：与肿瘤科护士相比，使用紫杉烷类治疗的转移性乳腺癌患者的效用。
6. Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane [O] . Joseph A. Sparano, Eduard Vrdoljak, Oliver Rixe, -1

机译：伊沙贝比隆加卡培他滨与卡培他滨对以前用蒽环类和紫杉烷类药物治疗的转移性乳腺癌患者的随机III期试验
7. Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane [O] . Sparano, Joseph A., Vrdoljak, Eduard, Rixe, Oliver, 2010

机译：伊沙贝比隆加卡培他滨与卡培他滨对以前用蒽环类和紫杉烷类药物治疗的转移性乳腺癌患者的随机III期试验

2101 ORAL Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting

著录项

相似文献

相关主题

期刊订阅